Compare ARK Innovation ETF (ARKK) vs Nuvalent Inc (NUVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Innovation ETF vs Nuvalent Inc — how do they compare? ARK Innovation ETF trades at $79.65, while Nuvalent Inc trades at $123.9 (market cap $9.80B). The key difference: Nuvalent Inc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | NUVL | |
|---|---|---|
52-Week High | $92.50 | $123.90 |
52-Week Low | $63.52 | $72.16 |
Market Cap | — | $9.80B |
Sector | — | Technology |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
Nuvalent (NUVL) trades at $123.9, up 0.06% on the day, following GSK's $10.6 billion all-cash acquisition offer at $124 per share announced on June 9, 2026 (Reuters). The stock is near the acquisition price, with bullish technical signals from moving averages but overbought RSI readings. Financially, the company reports negative earnings and cash flow from operations, with a P/B ratio of 8.35. Recent news highlights multiple law firms investigating the fairness of the deal.
The acquisition by GSK provides a clear exit near current levels, limiting upside but reducing volatility. Key risks include deal completion uncertainty and shareholder litigation. Analyst sentiment is mixed with 42% buy ratings. Investors should weigh the guaranteed offer against fundamental weaknesses and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
